Tarah J. Ballinger, MD, discusses the impact of SABCS 2023, focusing on the INAVO120 study for HR+/HER2- metastatic breast cancer. The study showed notable improvement in progression-free survival by adding inavolisib upfront in high-risk patients with PIK3CA/AKT pathway mutations. This has prompted a shift in Dr Ballinger's approach to genomic sequencing, leading to a more personalized workflow and increased upfront sequencing for patients.
In the curative setting, Dr Ballinger highlights data from the NATALEE trial involving adjuvant ribociclib and identifies clinical scenarios where ribociclib could be beneficial, particularly for high-risk patients not meeting the criteria to receive abemaciclib.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: SABCS 2023: The Clinical Implications of Findings in HR+/HER2- Breast Cancer - Medscape - Dec 27, 2023.
Comments